Mayer EL - Search Results

1

Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer.

Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M, Kirkner GJ, Rotem D, Cohen O, Yu F, Fitarelli-Kiehl M, Leong KW, Hughes ME, Rosenberg SM, Collins LC, Miller KD, Blumenstiel B, Trippa L, Cibulskis C, Neuberg DS, DeFelice M, Freeman SS, Lennon NJ, Wagle N, Ha G, Stover DG, Choudhury AD, Getz G, Winer EP, Meyerson M, Lin NU, Krop I, Love JC, Makrigiorgos GM, Partridge AH, Mayer EL, Golub TR, Adalsteinsson VA. Parsons HA, et al. Among authors: mayer el. Clin Cancer Res. 2020 Jun 1;26(11):2556-2564. doi: 10.1158/1078-0432.CCR-19-3005. Epub 2020 Mar 13. Clin Cancer Res. 2020. PMID: 32170028 Free PMC article.

2

Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.

Burstein HJ, Mayer E, Patridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HB, Winter EP, Garber JE. Burstein HJ, et al. Clin Breast Cancer. 2006 Jun;7(2):158-61. doi: 10.3816/cbc.2006.n.026. Clin Breast Cancer. 2006. PMID: 16800976

3

Novel approaches to advanced breast cancer: bevacizumab and lapatinib.

Mayer EL, Lin NU, Burstein HJ. Mayer EL, et al. J Natl Compr Canc Netw. 2007 Mar;5(3):314-23. doi: 10.6004/jnccn.2007.0026. J Natl Compr Canc Netw. 2007. PMID: 17439759 Review.

4

Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer.

Mayer EL, Carey LA, Burstein HJ. Mayer EL, et al. Breast Cancer Res. 2007;9(5):110. doi: 10.1186/bcr1755. Breast Cancer Res. 2007. PMID: 17888189 Free PMC article.

5

Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.

Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Partridge AH, et al. J Clin Oncol. 2008 Feb 1;26(4):556-62. doi: 10.1200/JCO.2007.11.5451. Epub 2008 Jan 7. J Clin Oncol. 2008. PMID: 18180462

6

Patient adherence and persistence with oral anticancer treatment.

Ruddy K, Mayer E, Partridge A. Ruddy K, et al. CA Cancer J Clin. 2009 Jan-Feb;59(1):56-66. doi: 10.3322/caac.20004. CA Cancer J Clin. 2009. PMID: 19147869 Free article. Review.

7

Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.

Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, Winer EP. Mayer EL, et al. Breast Cancer Res Treat. 2009 Oct;117(3):615-23. doi: 10.1007/s10549-009-0366-5. Epub 2009 Mar 18. Breast Cancer Res Treat. 2009. PMID: 19294501 Free PMC article. Clinical Trial.

8

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Mayer EL, Krop IE. Mayer EL, et al. Clin Cancer Res. 2010 Jul 15;16(14):3526-32. doi: 10.1158/1078-0432.CCR-09-1834. Clin Cancer Res. 2010. PMID: 20634194 Review.

9

Cardiac toxicity from systemic cancer therapy: a comprehensive review.

Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Curigliano G, et al. Among authors: mayer el. Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):94-104. doi: 10.1016/j.pcad.2010.05.006. Prog Cardiovasc Dis. 2010. PMID: 20728696 Review.

10

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA. Choueiri TK, et al. Among authors: mayer el. J Clin Oncol. 2011 Feb 20;29(6):632-8. doi: 10.1200/JCO.2010.31.9129. Epub 2011 Jan 4. J Clin Oncol. 2011. PMID: 21205755

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

126 results

Search Page